2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Treatment Considerations, Non-Biological Therapies, Anticoagulant Drugs, Clinical Practice (Health Services and Quality), Patient Safety, Quality Improvement, Quality of Care, Diseases, Bleeding and Clotting, Platelet Disorders, Thrombocytopenias, Thrombotic Disorders, Immunology, Infectious Diseases, Bacterial, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Study Population, Human, Adult, Pediatric
PAPER

4844 Long-term outcomes in thrombotic thrombocytopenic purpura across two treatment eras: A propensity-matched trinetx study

Sumit Saurav Karna, MD, Love Kumar, MD2, Jennifer Elizabeth Collins, PhD3, Amir Kamran, MD4
1 Vandalia Health - Charleston Area Medical Center, Charleston, West Virginia, United States
2 Vandalia Health - Charleston Area Medical Center, Charleston, West Virginia, United States
3 Vandalia Health - Charleston Area Medical Center, Charleston, West Virginia, United States
4 Vandalia Health - Charleston Area Medical Center, Charleston, West Virginia, United States

Background

The management of thrombotic thrombocytopenic purpura (TTP) has evolved considerably over the past decade with advances in diagnosis, treatment and monitoring. Whether these advances have resulted in improved long-term outcomes remains uncertain. We compared overall survival and major long-term outcomes among patients diagnosed during 2012–2018 and 2019–2025.

Methods

We conducted a retrospective propensity score-matched cohort study using the TriNetX Research Network. Adults diagnosed with TTP during 2012–2018 and 2019–2025 were identified after excluding secondary thrombotic microangiopathies. Therapeutic apheresis was evaluated as an indicator for relapse after excluding patients with myasthenia gravis, Guillain-Barré syndrome, and anti-glomerular basement membrane disease. Before matching, 972 patients in the earlier cohort and 6,120 in the contemporary cohort met inclusion criteria. Propensity score matching yielded 972 matched pairs. Median follow-up was 60 months in the earlier cohort and 24 months in the contemporary cohort. To account for differential follow-up and right-censoring, time-to-event analysis was performed using Kaplan–Meier methods with Cox proportional hazards regression and evaluated at 1, 3, and 5 years.

Results:

Patients diagnosed during 2019–2025 had better overall survival than those diagnosed during 2012–2018, with 5-year survival of 93% versus 89% (log-rank p=0.029), with similar differences at 3 years (94% vs. 91%, p=0.041) and 1 year (96% vs. 94%, p=0.022). Consistent with these findings, the patients diagnosed during 2012–2018 had a higher risk of mortality at 1 year (HR 1.66, 95% CI 1.07–2.57), 3 years (HR 1.47, 95% CI 1.01–2.13), and 5 years (HR 1.49, 95% CI 1.04–2.13).

Subsequent therapeutic apheresis was less common among patients diagnosed during 2019–2025, corresponding to a significantly higher hazard in the 2012–2018 cohort at 1 year (HR 4.28, 95% CI 2.35–7.80), 3 years (HR 2.96, 95% CI 1.92–4.58), and 5 years (HR 2.83, 95% CI 1.88–4.28). Similarly, stroke or transient ischemic attack occurred more frequently in the 2012-2018 cohort at 3 years (HR 1.48, 95% CI 1.06–2.08). Rates of heart failure, acute myocardial infarction, kidney injury, neurocognitive disorders, anxiety, and depression were similar between the two groups.

Conclusions

Patients diagnosed with TTP during 2019–2025 had improved long-term survival and required less subsequent therapeutic apheresis than those diagnosed during 2012–2018, suggesting meaningful progress in contemporary TTP management. Despite these improvements, long-term cardiovascular, neurologic, and psychiatric complications remain an important burden for TTP survivors.

 

Sumit Saurav Karna, MD: No relevant conflicts of interest to declare.